arXiv:2605.08767v2 Announce Type: replace Abstract: Recent advances in generative modeling have enabled significant progress in structure-based drug design (SBDD). Existing methods typically condition molecule generation on empty binding pockets from holo complexes, overlooking informative components such as the filler (ligands and solvent). Here, we leverage low-resolution electron density (ED) derived from the filler as a physically grounded condition for \textit{de novo} drug design. We consider two types of ED, calculated and cryo-EM/X-ray, obtainable from computational or experimental sou
Advances in generative AI models and improved computational methods for electron density analysis are converging, making this approach to drug design feasible and timely.
This development represents a significant methodological leap in AI-driven drug discovery, potentially accelerating the identification of new therapeutics by leveraging richer physical information.
Drug design traditionally relying on empty binding pockets can now incorporate more comprehensive molecular environment data (electron density) to improve generation accuracy and novelty.
- · Pharmaceutical companies
- · Biotechnology startups
- · AI drug discovery platforms
- · Computational chemists
- · Traditional drug discovery methods
- · Companies slow to adopt AI-driven SBDD
More efficient and targeted drug candidate generation for various diseases.
Reduced R&D costs and shortened timelines for bringing new drugs to market.
An acceleration in the discovery of novel treatments for previously intractable diseases, leading to improved public health outcomes.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.AI